Mycobacterium shimoidei cavitary pneumonia: A rare case report, literature review

IF 1.9 Q3 INFECTIOUS DISEASES

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Pub Date : 2025-04-27 DOI:10.1016/j.jctube.2025.100530

Siddartha Guru, David Ingram

{"title":"Mycobacterium shimoidei cavitary pneumonia: A rare case report, literature review","authors":"Siddartha Guru, David Ingram","doi":"10.1016/j.jctube.2025.100530","DOIUrl":null,"url":null,"abstract":"<div><div><em>Mycobacterium shimoidei</em> is a rare non-tuberculous mycobacterium (NTM) which causes pneumonia. Since its discovery in 1975, less than 50 cases have been published and this would be only the fourth case in the US. We present a case of <em>Mycobacterium shimoidei</em> in a 72-year-old male with symptoms of cough, dyspnea, and weight loss with cavitary lung lesion on imaging. Sputum cultures grew <em>Mycobacterium shimoidei</em> in two separate collections, and the patient was treated with oral azithromycin, ethambutol, and rifabutin empirically. Though due to medication side effects rifabutin was stopped and other antibiotics were attempted based on susceptibilities but he was unable to tolerate any of them. Thus, only a two-drug regimen including ethambutol and azithromycin was used, on which he improved clinically and cavitary lung lesions decreased in size. In addition, we did a literature review and compiled 41 previously published cases of <em>Mycobacterium shimoidei.</em></div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"40 ","pages":"Article 100530"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S240557942500021X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Mycobacterium shimoidei is a rare non-tuberculous mycobacterium (NTM) which causes pneumonia. Since its discovery in 1975, less than 50 cases have been published and this would be only the fourth case in the US. We present a case of Mycobacterium shimoidei in a 72-year-old male with symptoms of cough, dyspnea, and weight loss with cavitary lung lesion on imaging. Sputum cultures grew Mycobacterium shimoidei in two separate collections, and the patient was treated with oral azithromycin, ethambutol, and rifabutin empirically. Though due to medication side effects rifabutin was stopped and other antibiotics were attempted based on susceptibilities but he was unable to tolerate any of them. Thus, only a two-drug regimen including ethambutol and azithromycin was used, on which he improved clinically and cavitary lung lesions decreased in size. In addition, we did a literature review and compiled 41 previously published cases of Mycobacterium shimoidei.

查看原文本刊更多论文

希莫氏分枝杆菌空洞性肺炎1例，文献复习

shimoidei分枝杆菌是一种罕见的引起肺炎的非结核分枝杆菌（NTM）。自1975年发现以来，发表的病例不到50例，这将是美国的第4例。我们报告一名72岁男性的shimoidei分枝杆菌病例，其症状为咳嗽，呼吸困难，体重减轻，影像学上有肺空洞病变。痰培养在两个不同的标本中培养出shimoidei分枝杆菌，患者经口服阿奇霉素、乙胺丁醇和利福布汀治疗。虽然由于药物副作用，利福布汀被停药，其他抗生素也被尝试过，但他无法忍受任何一种抗生素。因此，仅使用乙胺丁醇和阿奇霉素两种药物治疗方案，他的临床症状得到改善，肺空洞病变大小减小。此外，我们还进行了文献回顾，并汇编了41例先前发表的shimoidei分枝杆菌病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Medicine-Pulmonary and Respiratory Medicine

CiteScore

4.00

自引率

5.00%

发文量

审稿时长

30 weeks

期刊介绍： Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.